Primary breast carcinoma: Association of mammographic calcifications with osteopontin expression

Radiology

Volumn 254, Issue 1, 2010, Pages 69-78

  Wang, Xiao ^a   Chao, Lan ^b   Ma, Guohui ^a   Chen, Liansheng ^a   Jin, Guangchao ^a   Hua, Mei ^a   Liu, Huiping ^a   Ouyang, Aimei ^a   Zhang, Xiulan ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPONTIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; BREAST CALCIFICATION; BREAST CARCINOMA; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; FEMALE; HUMAN; IMAGING SYSTEM; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; AGED; BREAST TUMOR; CALCINOSIS; CANCER INVASION; CHI SQUARE DISTRIBUTION; ENZYME IMMUNOASSAY; METABOLISM; MIDDLE AGED; PHENOTYPE; RADIOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CALCINOSIS; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MAMMOGRAPHY; MIDDLE AGED; NEOPLASM INVASIVENESS; OSTEOPONTIN; PHENOTYPE; RETROSPECTIVE STUDIES;

EID: 75349107743     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2541090675     Document Type: Article

References (45)

1. Evans AJ, Pinder SE, Ellis IO, et al. Correlations between the mammographic features of ductal carcinoma in situ (DCIS) and C-erbB-2 oncogene expression. Clin Radiol 1994;49:559-562.
2. Karamouzis MV, Likaki-Karatza E, Ravazoula P, et al. Non-palpable breast carcinomas: correlation of mammographically detected malignant-appearing microcalcifications and molecular prognostic factors. Int J Cancer 2002;102:86-90.
3. Seo BK, Pisano ED, Kuzimak CM, et al. Correlation of HER-2/neu overexpression with mammography and age distribution in primary breast carcinomas. Acad Radiol 2006;13:1211-1218.
4. Wang Y, Ikeda DM, Narasimhan B, et al. Estrogen receptor-negative invasive breast cancer:imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression. Radiology 2008;246:367-375.
5. Wang X, Chao L, Chen L, et al. Correlation of mammographic calcifications with HER-2/neu overexpression in primary breast carcinomas. J Digit Imaging 2008;21:170-176.
6. Rangaswami H, Bulbule A, Kundu GC, et al. Osteopontin:role in cell signaling and cancer progression. Trends Cell Biol 2006;16:79-87.
7. Chakraborty G, Jain S, Behera R, et al. The multifaceted role of Osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 2006;6:819-830.
8. Matusan K, Dordevic G, Stipic D, Mozetic V, Lucin K. Osteopontin expression correlates with prognostic variables and survival in clear cell renal cell carcinoma. J Surg Oncol 2006;94:325-331.
9. Rudland PS, Platt-Higgins A, El-Tanani M, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002;62:3417-3427.
10. Tuck AB, O'Malley FP, Singhal H, et al. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 1997;121:578-584.
11. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancers subtype, and survival in the Carolina breast cancer study. JAMA 2006;295:2492-2502.
12. Sorlie T, Perou CM, Tibshirani R, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100:8418-8423.
13. Wang X, Chao L, Ma G, et al. Increased expression of osteopontin in patients with triple-negative breast cancer. Eur J Clin Invest 2008;38:438-446.
14. Oyama T, Sano T, Hikino T, et al. Micro-calcifications of breast cancer and atypical cystic lobules associated with infiltration of foam cells expressing osteopontin. Virchows Arch 2002;440:267-273.
15. Bellahcène A, Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol 1995;146:95-100.
16. Obenauer S, Hermann KP, Grabbe E. Applications and literature review of the BI-RADS classification. Eur Radiol 2005; 15:1027-1036.
17. American College of Radiology. Breast imaging reporting and data system (BIRADS). 4th ed. Reston, Va: American College of Radiology, 2003.
18. Tuck AB, Chambers AF, Allanl AL. Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem 2007;102:859-868.
19. Tuck AB, Hota C, Chambers AF. Osteopontin (OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Res Treat 2001;70:197-204.
20. Tuck AB, O'Malley FP, Singhal H, et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 1998;79:502-508.
21. Thurfjell E, Thurfjell MG, Lindgren A. Mammographic finding as predictor of survival in 1-9 mm invasive breast cancers: worse prognosis for cases presenting as calcifications alone. Breast Cancer Res Treat 2001;67:177-180.
22. Tabar L, Chen HH, Duffy SW, et al. A novel method for prediction of long-term outcome of women with T1a, T1b, and 10-14 mm invasive breast cancers:a prospective study. Lancet 2000;355:429-433.
23. Tot T. The metastatic capacity of multifocal breast carcinomas: extensive tumors versus tumors of limited extent. Hum Pathol 2009;40:199-205.
24. Kang DK, Jeon GS, Yim H, Jung YS. Diagnosis of the intraductal component of invasive breast cancer: assessment with mammography and sonography. J Ultrasound Med 2007;26:1587-1600.
25. Ribeiro-Silva A, Oliveira da Costa JP. Osteopontin expression according to molecular profile of invasive breast cancer: a clinicopathological and immunohistochemical study. Int J Biol Markers 2008;23:154-160.
26. Oates AJ, Barraclough R, Rudland PS. The identification of osteopontin as a mestastasisrelated gene product in a rodent mammary tumor model. Oncogene 1996;13:97-104.
27. Khan SA, Cook AC, Kappil M, et al. Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration. Clin Exp Metastasis 2005;22:663-673.
28. Parikh RR, Housman D, Qifeng Y, Toppmeyer D, Wilson LD, Haffty BG. Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer. Int J Radiat Oncol Biol Phys 2008;72:1056-1063.
29. Hirota S, Ito A, Nagoshi J, et al. Expression of bone matrix protein messenger ribonucleic acids in human breast cancers: possible involvement of osteopontin in development of calcifying foci. Lab Invest 1995;72:64-69.
30. Hunter GK, Kyle CL, Goldberg HA. Modulation of crystal formation by bone phosphoproteins:structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation. Biochem J 1994; 300:723-728.
31. Hunter GK, Hauschka PV, Poole AR, et al. Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. Biochem J 1996;317:59-64.
32. Allan AL, George R, Vantyghem SA, et al. Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol 2006;169:233-246.
33. Gajdos C, Tartter PI, Bleiweiss IJ, et al. Mammographic appearance of nonpalpable breast cancer reflects pathologic characteristics. Ann Surg 2002;235:246-251.
34. Boulet S, Tixier H, Fraisse J, et al. Sentinel lymph node biopsy in two Burgundy districts: prospective multicentric study on 528 breast cancers during the year 2005. Arch Gynecol Obstet doi.10.1007/s00404-009-1163-4. Published online June 24, 2009.
35. Canavese G, Catturich A, Vecchio C, et al. Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial. Ann Oncol 2009;20:1001-1007.
36. Hong AS, Rosen EL, Soo MS, Baker JA. BIRADS for sonography: positive and negative predictive values of sonographic features. AJR Am J Roentgenol 2005;184:1260-1265.
37. Liberman L, Abramson AF, Squires FB, Glassman JR, Morris EA, Dershaw DD. The breast imaging reporting and data system: positive predictive value of mammographic features and final assessment categories. AJR Am J Roentgenol 1998;171:35-40.
38. Alexander MC, Yankaskas BC, Biesemier KW. Association of stellate mammographic pattern with survival in small invasive breast tumors. AJR Am J Roentgenol 2006;187:29-37.
39. Evans AJ, Kutt E, Record C, Waller M, Moss S. Radiological findings of screendetected cancers in a multi-centre randomized, controlled trial of mammographic screening in women from age 40 to 48 years. Clin Radiol 2006;61:784-788.
40. Singhal H, Bautista DS, Tonkin KS, et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997;3:605-611.
41. Martinetti A, Bajetta E, Ferrari L, et al. Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. Endocr Relat Cancer 2004;11:771-779.
42. Skaane P. Studies comparing screen-film mammography and full-field digital mammography in breast cancer screening: updated review. Acta Radiol 2009;50:3-14.
43. Ando M, Bando H, Endo T, et al. Refraction-based 2D, 2.5D and 3D medical imaging: stepping forward to a clinical trial. Eur J Radiol 2008;68 (3 suppl):S32-S36.
44. Porter G, Steel J, Paisley K, Watkins K, Holgate C. Incidental breast masses detected by computed tomography:are any imaging features predictive of malignancy? Clin Radiol 2009;64:529-533.
45. Ross JS. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome. Adv Anat Pathol 2009;16:204-215.